A new experimental pill reduces bad cholesterol levels by up to 60 percent, sparking hopes of a breakthrough in heart disease prevention. Researchers say the drug could be a game-changer for patients who do not respond well to statins or experience their side effects. Enlicitide, developed by Merck, was presented at the American Heart Association Scientific Sessions 2025 recently.